Literature DB >> 9189199

Surveillance mammography and stereotactic core breast biopsy for probably benign lesions: a cost comparison analysis.

R J Brenner1, E A Sickles.   

Abstract

RATIONALE AND
OBJECTIVES: The authors compared the economic effect of stereotactic core needle biopsy (CNB) with that of short-term unilateral surveillance mammography in the management of probably benign breast lesions detected during routine screening mammography.
METHODS: Published data with regard to the cost of stereotactic CNB and unilateral mammography were applied to 3,184 patients who underwent surveillance mammography; including 161 patients who underwent biopsy. Costs of immediate tissue diagnosis were compared with costs of surveillance with use of ratios of published reimbursement scales to minimize geographic variations. Sensitivity analyses were applied to this ratio.
RESULTS: The cost of managing probably benign breast lesions with surveillance mammography was $3,307,575 less than if all lesions had been managed with CNB. The ratio of the cost of CNB to the cost of surveillance mammography was 8:1. This ratio is more sensitive to the frequency of use of CNB than to reimbursement schedules.
CONCLUSION: With similar false-negative rates, CNB is more costly than surveillance and has a negative effect in the management of probably benign breast lesions, unless interval change during surveillance prompts tissue diagnosis.

Entities:  

Mesh:

Year:  1997        PMID: 9189199     DOI: 10.1016/s1076-6332(97)80048-7

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  4 in total

1.  BI-RADS Category 3 Comparison: Probably Benign Category after Recall from Screening before and after Implementation of Digital Breast Tomosynthesis.

Authors:  Elizabeth S McDonald; Anne Marie McCarthy; Susan P Weinstein; Mitchell D Schnall; Emily F Conant
Journal:  Radiology       Date:  2017-07-17       Impact factor: 11.105

2.  BI-RADS Category 3 Is a Safe and Effective Alternative to Biopsy or Surgical Excision.

Authors:  Linda Moy
Journal:  Radiology       Date:  2020-05-19       Impact factor: 11.105

3.  Probably benign lesions at screening breast US in a population with elevated risk: prevalence and rate of malignancy in the ACRIN 6666 trial.

Authors:  Richard G Barr; Zheng Zhang; Jean B Cormack; Ellen B Mendelson; Wendie A Berg
Journal:  Radiology       Date:  2013-10-28       Impact factor: 11.105

4.  MR-guided breast biopsy at 3T: diagnostic yield of large core needle biopsy compared with vacuum-assisted biopsy.

Authors:  Carla Meeuwis; Jeroen Veltman; Hester N van Hall; Roel D M Mus; Carla Boetes; Jelle O Barentsz; Ritse M Mann
Journal:  Eur Radiol       Date:  2011-09-14       Impact factor: 5.315

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.